Login / Signup

The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer's disease.

Chih-Sung LiangKuan-Pin SuChia-Lin TsaiJiunn-Tay LeeChe-Sheng ChuTa-Chuan YehMing-Wei SuGuan-Yu LinYu-Kai LinHsuan-Te ChuChia-Kuang TsaiFu-Chi Yang
Published in: Alzheimer's research & therapy (2020)
IL-33 or its associated signaling pathways may represent a new treatment paradigm for aMCI and AD.
Keyphrases
  • mild cognitive impairment
  • cognitive decline
  • signaling pathway
  • epithelial mesenchymal transition
  • pi k akt
  • replacement therapy